The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sriram, S.
Right arrow Articles by Ranges, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sriram, S.
Right arrow Articles by Ranges, G.

The Journal of Immunology, Vol 141, Issue 2 464-468, Copyright © 1988 by American Association of Immunologists

ARTICLES

In vivo immunomodulation by monoclonal anti-CD4 antibody. II. Effect on T cell response to myelin basic protein and experimental allergic encephalomyelitis

S Sriram, L Carroll, S Fortin, S Cooper and G Ranges
Department of Neurology, University of Vermont, Burlington 05405.

In vivo administration of anti-CD4 mAb (GK1.5) has been shown to be effective in preventing acute and relapsing experimental allergic encephalomyelitis (EAE). In the present report we have studied the depletion of CD4+ cells by a single dose of GK1.5 on the immune response to myelin basic protein and in the development of EAE. Our studies show that depletion of CD4 cells in mice that had received encephalitogenic CD4+ T cells altered the kinetics of acute and relapsing EAE, but did not prevent disease altogether. The in vitro T cell proliferative response to myelin basic protein in lymph node cells was maintained in the presence of significant depletion of CD4+ cells. These studies indicate that the population of Ag-reactive cells to be large and relatively refractory to antibody therapy. The implication of these results to therapy of human autoimmune disease is discussed.


This article has been cited by other articles:


Home page
 Int ImmunolHome page
G. T. Tran, N. Carter, X. Y. He, T. S. Spicer, K. M. Plain, M. Nicolls, B. M. Hall, and S. J. Hodgkinson
Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on Th1 cells that is augmented by IL-4
Int. Immunol., September 1, 2001; 13(9): 1109 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S.-Y. Yao, C. W. Stratton, W. M. Mitchell, and S. Sriram
CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens
Neurology, May 8, 2001; 56(9): 1168 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Cai, M. J. Spencer, G. Nakamura, L. Tseng-Ong, and J. G. Tidball
Eosinophilia of Dystrophin-Deficient Muscle Is Promoted by Perforin-Mediated Cytotoxicity by T Cell Effectors
Am. J. Pathol., May 1, 2000; 156(5): 1789 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. J. Bright, M. Rodriguez, and S. Sriram
Differential Influence of Interleukin-12 in the Pathogenesis of Autoimmune and Virus-Induced Central Nervous System Demyelination
J. Virol., February 1, 1999; 73(2): 1637 - 1639.
[Abstract] [Full Text]

Home page
 ScienceHome page
D.-R. Koh, W.-P. Fung-Leung, A. Ho, D. Gray, H. Acha-Orbea, and T.-W. Mak
Less Mortality but More Relapses in Experimental Allergic Encephalomyelitis in CD8-/- Mice
Science, May 22, 1992; 256(5060): 1210 - 1213.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.